Diagnostic capabilities and patient identification are critical determinants of the Castleman disease treatment market's ability to reach eligible patients and deliver timely, appropriate therapy. Castleman disease remains frequently misdiagnosed or delayed in diagnosis, with patients often enduring years of symptoms and multiple incorrect diagnoses before receiving appropriate treatment. The estimated diagnostic delay averages 2.5 years for iMCD, during which progressive organ dysfunction and cytokine-mediated damage accumulate. Advances in diagnostic criteria, biomarker identification, and histopathological classification are addressing these challenges. The Castleman Disease Collaborative Network's consensus diagnostic criteria for iMCD, published in 2017 and updated subsequently, established major and minor criteria encompassing histopathological findings, laboratory abnormalities, clinical symptoms, and exclusion of other conditions, improving diagnostic consistency across centers.

Biomarker discovery is transforming Castleman disease identification and monitoring. Castleman Disease Treatment Market analysis indicates that IL-6 levels, while elevated in many patients, are neither sensitive nor specific enough for standalone diagnosis, prompting investigation of broader cytokine panels including IL-1, TNF-alpha, VEGF, and soluble IL-2 receptor. The CDCN's ACCELERATE registry has identified a 34-cytokine signature that distinguishes iMCD from other inflammatory conditions with improved accuracy, with validation studies advancing. Over 2,400 patients were enrolled in the ACCELERATE registry by 2025, generating unprecedented natural history data.

Histopathological classification distinguishes hyaline vascular variant, plasma cell variant, and mixed variant Castleman disease, with plasma cell variant more commonly associated with systemic symptoms and requiring medical therapy. Next-generation sequencing of lymph node tissue has identified recurrent mutations in genes including ARID1A, SETD2, and RAS pathway genes in subsets of iMCD, suggesting potential for molecular subtyping that could guide targeted therapy selection. PET-CT imaging with standardized uptake values helps assess disease burden and treatment response, while whole-body MRI is emerging as a radiation-sparing alternative for longitudinal monitoring. The integration of clinical criteria, cytokine profiling, histopathology, molecular analysis, and advanced imaging is creating a multimodal diagnostic framework that reduces diagnostic delay, enables disease subtyping, and supports personalized treatment selection. As diagnostic awareness spreads among hematologists, internists, and emergency physicians, and as biomarker assays become commercially available, the identification of previously undiagnosed Castleman disease patients is expanding the treatable population and creating earlier intervention opportunities.

Q1: What is the average diagnostic delay for Castleman disease? The estimated diagnostic delay averages 2.5 years for iMCD, during which progressive organ dysfunction accumulates, highlighting the need for improved awareness and diagnostic criteria.

Q2: What biomarkers are being developed for Castleman disease diagnosis? Beyond IL-6, a 34-cytokine signature from the ACCELERATE registry distinguishes iMCD from other inflammatory conditions, with recurrent mutations in ARID1A, SETD2, and RAS pathway genes identified for molecular subtyping.

Q3: How is imaging used in Castleman disease diagnosis and monitoring? PET-CT with standardized uptake values assesses disease burden and treatment response, while whole-body MRI emerges as a radiation-sparing alternative for longitudinal monitoring of lymph node and organ involvement.